Abstract: Disclosed herein are dentifrices with low pH-triggered release of pharmacons and other materials to more effectively adhere to the tooth and associated surfaces. The various compositions and methods include novel dental compositions that release materials such as fluoride ions, eugenol, pharmacons or other medicinal payloads under physiologically low pH to extend the material lifespan on the teeth and gums of the user.

Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.

Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.

Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.

Abstract: The disclosure is directed to nanoparticles, compositions comprising nanoparticles, and methods of using the nanoparticles and compositions to introduce genetic material into a host cell, and in particular, a plant cell nucleus, to cause transformation of the host cell through the expression of genes on the introduced genetic material.

Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.

Abstract: Disclosed is a non-destructive universal method of functionalization of graphitic carbonaceous materials that enables their alignment, cross-linking, and effective integration into composite materials.

Abstract: The present invention relates to a method of remineralizing and desensitizing teeth utilizing the sequential steps of first applying to the teeth a first component that attaches to the teeth and secondly applying to the teeth treated with the first component a second component that attaches to the first component.

Abstract: Disclosed is a non-destructive universal method of functionalization of graphitic carbonaceous materials that enables their alignment, cross-linking, and effective integration into composite materials.

Abstract: The present invention relates to a method of remineralizing and desensitizing teeth utilizing the sequential steps of first applying to the teeth a first component that attaches to the teeth and secondly applying to the teeth treated with the first component a second component that attaches to the first component.

Abstract: A method for determining the efficacy of a vaccine comprising: providing serum from an animal inoculated with a vaccine; providing a plurality of antigen-linked nanoparticles; contacting the serum with the plurality of antigen linked nanoparticles; contacting the serum and the plurality of antigen linked nanoparticles with a plurality of Fc receptor-expressing cells; measuring amount antigen-linked nanoparticle uptake by of the Fc receptor-expressing cells; determining efficacy of the vaccine by comparing the level of antigen-linked nanoparticle uptake to a baseline level of uptake wherein a greater nanoparticle uptake compared to the baseline level of uptake is indicative of greater vaccine efficacy.